Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ARCT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -20.92M
March 31, 2026 -19.44M
December 31, 2025 -18.08M
September 30, 2025 -19.63M
June 30, 2025 -5.926M
March 31, 2025 -35.14M
December 31, 2024 -0.4598M
September 30, 2024 -23.83M
June 30, 2024 -29.85M
March 31, 2024 -5.557M
December 31, 2023 -0.5447M
September 30, 2023 -31.62M
June 30, 2023 50.57M
March 31, 2023 -35.87M
December 31, 2022 155.17M
September 30, 2022 -40.45M
June 30, 2022 -34.88M
March 31, 2022 -49.04M
December 31, 2021 -45.14M
September 30, 2021 -17.13M
June 30, 2021 -33.07M
March 31, 2021 -42.95M
December 31, 2020 -7.393M
September 30, 2020 -16.53M
June 30, 2020 -8.457M
Date Value
March 31, 2020 -11.86M
December 31, 2019 -7.691M
September 30, 2019 -2.838M
June 30, 2019 9.366M
March 31, 2019 -5.411M
December 31, 2018 -5.482M
September 30, 2018 -6.599M
June 30, 2018 -7.709M
March 31, 2018 -0.361M
December 31, 2017 10.11M
September 30, 2017 -1.403M
June 30, 2017 -4.211M
March 31, 2017 -4.964M
December 31, 2016 -3.90M
September 30, 2016 -6.734M
June 30, 2016 -4.207M
March 31, 2016 -4.437M
December 31, 2015 -4.156M
September 30, 2015 -5.458M
June 30, 2015 -3.975M
March 31, 2015 -4.595M
December 31, 2014 -6.020M
September 30, 2014 -9.298M
June 30, 2014 -5.518M
March 31, 2014 -5.628M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 307.74M
PTC Therapeutics, Inc. 129.11M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M